MFAP1

Across TCGA pan-cancer cohorts, MFAP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFAP1 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MFAP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFAP1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

KIRP, SKCM, and PRAD are the cancer types where MFAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.127	0.859	<.001	48	view →
SKCM	OS	Median	II,III,IV	0.233	0.739	.020	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	III,IV	1.000	0.273	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MFAP1–KIRP (OS)

Open the KIRP breakdown →